Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467200 | 0.85 | ALDH1A1 (0.64) | LMNAALDH1A1HSD17B10MEN1GLA | |
| SCHEMBL5467091 | 0.84 | KDM4E (0.46) | CNR2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL14597113 | 0.83 | LMNA (0.47) | LMNAALDH1A1HSD17B10MEN1GLA | |
| SCHEMBL5472658 | 0.81 | MEN1 (0.56) | LMNAALDH1A1HSD17B10MEN1GLA | |
| SCHEMBL5467235 | 0.81 | PKM (0.52) | LMNAALDH1A1HSD17B10MEN1GLA | |
| SCHEMBL5470732 | 0.79 | ALDH1A1 (0.53) | LMNAALDH1A1HSD17B10MEN1GLA | |
| SCHEMBL5470611 | 0.77 | KDM4E (0.60) | ALDH1A1HSD17B10MEN1GAAHPGD | |
| SCHEMBL5461017 | 0.76 | KMT2A (0.54) | LMNAALDH1A1HSD17B10MEN1GAA | |
| SCHEMBL5471874 | 0.76 | GNRHR (0.49) | CNR2LMNAALDH1A1MEN1GAA | |
| SCHEMBL5464451 | 0.76 | ALDH1A1 (0.53) | LMNAALDH1A1MEN1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | CNR2 1147/4885LMNA 2632/4885ALDH1A1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.